Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression.

Rusciani L, Proietti I, Rusciani A, Paradisi A, Sbordoni G, Alfano C, Panunzi S, De Gaetano A, Lippa S.

J Am Acad Dermatol. 2006 Feb;54(2):234-41. Epub 2005 Dec 27.

PMID:
16443053
2.

Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.

Domingo-Domènech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascón P, Mellado B, Molina R.

Tumour Biol. 2007;28(5):264-72. Epub 2007 Oct 26.

PMID:
17962723
3.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951.

J Clin Oncol. 2007 Apr 20;25(12):1562-9.

4.

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.

Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H.

Cancer. 2006 Mar 1;106(5):1130-9. Erratum in: Cancer. 2006;107(9 No 1):2315.

5.

Coenzyme Q10 in plasma and erythrocytes: comparison of antioxidant levels in healthy probands after oral supplementation and in patients suffering from sickle cell anemia.

Niklowitz P, Menke T, Wiesel T, Mayatepek E, Zschocke J, Okun JG, Andler W.

Clin Chim Acta. 2002 Dec;326(1-2):155-61.

PMID:
12417107
6.

Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.

Wakamatsu K, Kageshita T, Furue M, Hatta N, Kiyohara Y, Nakayama J, Ono T, Saida T, Takata M, Tsuchida T, Uhara H, Yamamoto A, Yamazaki N, Naito A, Ito S.

Melanoma Res. 2002 Jun;12(3):245-53.

PMID:
12140381
7.

Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.

Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W.

Br J Dermatol. 2008 Sep;159(3):597-605. doi: 10.1111/j.1365-2133.2008.08710.x. Epub 2008 Jul 4.

PMID:
18616789
8.

Circulating vascular endothelial growth factor in cutaneous malignant melanoma.

Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, Laurent R, Humbert P, Aubin F.

Br J Dermatol. 2005 Apr;152(4):685-9.

PMID:
15840099
9.

Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.

Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T.

Melanoma Res. 2002 Jun;12(3):255-62.

PMID:
12140382
10.

Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases.

Bastiaannet E, Hoekstra OS, Oyen WJ, Jager PL, Wobbes T, Hoekstra HJ.

Ann Surg Oncol. 2006 Jul;13(7):919-26. Epub 2006 May 23.

PMID:
16788752
11.

Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.

Rusciani L, Proietti I, Paradisi A, Rusciani A, Guerriero G, Mammone A, De Gaetano A, Lippa S.

Melanoma Res. 2007 Jun;17(3):177-83.

PMID:
17505263
12.

Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.

Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardò T, Fierro MT, Cavallo F, Savoia P, Bernengo MG.

Melanoma Res. 2007 Apr;17(2):75-82.

PMID:
17496782
13.

[The antioxidants (coenzyme Q10) in materno-fetal physiopathology].

Noia G, Romano D, De Santis M, Cavaliere AF, Straface G, Alcaino S, Di Domenico M, Petrone A, Caruso A, Mancuso S.

Minerva Ginecol. 1999 Oct;51(10):385-91. Italian.

PMID:
10638164
14.

Plasma coenzyme Q10 levels and postmenopausal breast cancer risk: the multiethnic cohort study.

Chai W, Cooney RV, Franke AA, Shvetsov YB, Caberto CP, Wilkens LR, Le Marchand L, Henderson BE, Kolonel LN, Goodman MT.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2351-6. doi: 10.1158/1055-9965.EPI-10-0396. Epub 2010 Jul 28.

15.
16.

A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium.

Khan M, Gross J, Haupt H, Jainz A, Niklowitz P, Scherer H, Schmidt FP, Klapp BF, Reisshauer A, Mazurek B.

Otolaryngol Head Neck Surg. 2007 Jan;136(1):72-7.

PMID:
17210337
17.

Plasma coenzyme Q10 concentrations are not decreased in male patients with coronary atherosclerosis.

van de Vijver LP, Weber C, Kardinaal AF, Grobbee DE, Princen HM, van Poppel G.

Free Radic Res. 1999 Mar;30(3):165-72.

PMID:
10711786
18.

Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.

Gogas H, Trakatelli M, Dessypris N, Terzidis A, Katsambas A, Chrousos GP, Petridou ET.

Ann Oncol. 2008 Feb;19(2):384-9. Epub 2007 Oct 8.

19.

Decreased coenzyme Q10 concentration in plasma of children with cystic fibrosis.

Oudshoorn JH, Lecluse AL, van den Berg R, Vaes WH, van der Laag J, Houwen RH.

J Pediatr Gastroenterol Nutr. 2006 Nov;43(5):646-50.

PMID:
17130743
20.

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S.

Oncologist. 2009 Oct;14(10):995-1002. doi: 10.1634/theoncologist.2009-0083. Epub 2009 Sep 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk